Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CD24 Protein-VLP (AA 26-57)

Protéine VLP CD24 exprimée dans HEK-293 Cells.
N° du produit ABIN7448155

Aperçu rapide pour CD24 Protein-VLP (AA 26-57) (ABIN7448155)

Antigène

Voir toutes CD24 Protéines
CD24 (CD24 Molecule (CD24))

Type de proteíne

VLP

Activité biologique

Active

Origine

  • 22
  • 5
  • 3
  • 1
Cynomolgus

Source

  • 19
  • 4
  • 3
  • 3
  • 2
HEK-293 Cells

Application

ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Pureté

> 90 % as determined by HPLC
  • Attributs du protein

    AA 26-57

    Fonction

    Cynomolgus CD24 Protein-VLP

    Séquence

    Ser26-Gly57

    Attributs du produit

    Recombinant Cynomolgus CD24 Protein-VLP is expressed from HEK293.It contains Ser26-Gly57.

    Stérilité

    0.22 μm filtered

    niveau d'endotoxine

    Less than 1EU per μg by the LAL method.
  • Vous souhaitez d'autres options pour ce Protein ?

    !
    Découvrez nos protéines personnalisées prédéfinies et nos services de protéines sur mesure !

    Votre projet nécessite-t-il une personnalisation supplémentaire ? Contactez-nous et découvrez nos solutions protéiques sur mesure

  • Indications d'application

    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA

    Commentaires

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.

    Stock

    -80 °C

    Stockage commentaire

    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

    Date de péremption

    12 months
  • Antigène

    CD24 (CD24 Molecule (CD24))

    Autre désignation

    CD24

    Sujet

    CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

    Poids moléculaire

    3.8 kDa.

    NCBI Accession

    XP_015304503

    Pathways

    Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation
Vous êtes ici:
Chat with us!